Results 201 to 210 of about 41,661 (291)

Neoadjuvant androgen deprivation therapy with bicalutamide compared to hormonal agents in treating high-risk prostate cancer: a real-world cohort study. [PDF]

Transl Cancer Res
Liu J, Cui Y, Tang X, Ma J, Du P.
europepmc   +1 more source

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer

The Prostate, Volume 86, Issue 9, Page 1043-1052, June 15, 2026.
ABSTRACT Purpose Previous studies have demonstrated an association between PSMA‐PET SUVmax and poorer survival outcomes in patients with mCRPC. However, limited data are available in mHSPC. We aim to investigate the relationship between baseline PSMA‐PET SUVmax and rPFS in patients with mHSPC.
Cevat İlteriş Kıkılı, Caner Kapar, Feyyaz Hazar Yağmur, Esra Arslan, Bahadır Köylü, Fatih Kemik, Buğra Han Esen, Nazan Demir, İlkay Gültürk, Murat Polat, Fatih Selçukbiricik, Deniz Tural   +11 more
wiley   +1 more source

Standardized Program of Resistance Training for Prostate Cancer Patients Receiving Androgen Deprivation Therapy (SPoRT-PCa-ADT): study protocol for a randomized controlled trial. [PDF]

BMC Cancer
Soler-López A, Gómez-Carmona CD, González-Devesa D, López-Plaza D, Herrero-Vidal L, Toledo-Pozuelo R, González-Costea A, Cao-Avellaneda E.   +7 more
europepmc   +1 more source

Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer

The Prostate, Volume 86, Issue 9, Page 1053-1060, June 15, 2026.
ABSTRACT Background Early deep prostate‐specific antigen (PSA) decline after the initiation of androgen receptor signaling inhibitor (ARSI) therapy is associated with favorable long‐term outcomes in metastatic castration‐sensitive prostate cancer (mCSPC).
Kazuma Yukihiro, Yohei Sekino, Keisuke Goto, Kohei Saito, Kenta Fujiyama, Yoshito Kagiyama, Yoshimasa Kurimura, Kenichiro Fukuoka, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +14 more
wiley   +1 more source

Long-term assessment of adverse cardiovascular events in men receiving intermittent androgen deprivation therapy following radical prostatectomy. [PDF]

BJUI Compass
Tran J, Hwang Y, Nguyen MX, Mendoza G, Huang E, Huynh L, Gevorkyan R, Fung C, Wilson R, Greenfield S, Ahlering T.   +10 more
europepmc   +1 more source

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target

The Prostate, Volume 86, Issue 9, Page 1061-1068, June 15, 2026.
ABSTRACT Introduction The clinical relevance of HER2 expression profile in solid cancers has expanded with the evolving landscape of HER2 targeting agents. This systematic review and meta‐analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression.
Jacky T. F. Luk, Alex H. Lin, Esther K. C. Cheung, Renald Meçani, Taulant Muka, Jana Nano, Joanna K. M. Ng, Matthew K. L. Chiu, Bryan C. W. Li, Rong Na, Joshua J. X. Li   +10 more
wiley   +1 more source

Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP). [PDF]

Future Oncol
Morgans AK, Chehrazi-Raffle A, Niazi T, Shore ND, Ross AE, Røder A, Gomes AJ, Supiot S, Barthélémy P, Hatano K, Ruiz CBC, Yoshida S, Herrera-Imbroda B, Gratton M, Gschwend JE, Hope TA, Joensuu H, Kuss I, Le Berre MA, Dimova-Dobreva M, Fizazi K.   +20 more
europepmc   +1 more source

Prostate Cancer, Genetic Susceptibility, and Risk of Chronic Non‐Urological Complications

The Prostate, Volume 86, Issue 9, Page 1083-1090, June 15, 2026.
ABSTRACT Background Chronic nonurological complications are common among prostate cancer (PCa) survivors; however, their spectrum, magnitude, and genetic contribution remain poorly characterized. Methods We evaluated 15 commonly reported nonurological complications and tested their associations with exposure to PCa and disease‐specific polygenic risk ...
Brian T. Helfand, Zhuqing Shi, Ashley J. Mulford, Huy Tran, Jun Wei, Annabelle Ashworth, S. Lilly Zheng, Alan R. Sanders, Nathan Graham, Joshua Cabral, Jim Lu, Jennifer L. Beebe‐Dimmer, Kathleen A. Cooney, David Duggan, Jianfeng Xu   +14 more
wiley   +1 more source

TAM Plasticity under androgen deprivation therapy and PARP inhibition in prostate cancer: a multi-omics perspective. [PDF]

Front Immunol
Chen S, Cai W, Liu C.
europepmc   +1 more source